Serum biomarker profiles suggest that atopic dermatitis is a systemic disease

• Published in: Journal of allergy and clinical immunology Vol. 141; no. 4; pp. 1523 - 1526
• Main Authors: Thijs, Judith L., Strickland, Ian, Bruijnzeel-Koomen, Carla A.F.M., Nierkens, Stefan, Giovannone, Barbara, Knol, Edward F., Csomor, Eszter, Sellman, Bret R., Mustelin, Tomas, Sleeman, Matthew A., de Bruin-Weller, Marjolein S., Herath, Athula, Drylewicz, Julia, May, Richard D., Hijnen, DirkJan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2018; Elsevier Limited
• Subjects: Adult; Animals; Asthma; Asthma - blood; Atopic dermatitis; Biomarkers; Biomarkers - blood; Cluster analysis; Cytokines; Dermatitis; Dermatitis, Atopic - blood; Female; Health risk assessment; Humans; Hypotheses; Inflammation; Inflammation - blood; Male; Mice; Mice, Transgenic; Pathogenesis; Rheumatoid arthritis; Studies; Systemic diseases; Asia; North America; Europe
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2017.12.991

The component loadings showed that principal component 1 (explaining 23% of variability) is primarily driven by IL-5, IL-1β, IL-7, IL-1R1, and IL-15; principal component 2 (explaining 12% of variability) by IFN-β, IL-20, IL-1Rα, TNF-β, and monocyte chemoattractant protein-3 (MCP-3); and principal component 3 (explaining 6% of the variation) by tissue inhibitor of metalloproteinase 1, cathepsin-S, intercellular adhesion molecule 1, pulmonary and activation-regulated chemokine, and angiotensin-converting enzyme (ACE). Associations among AD, cardiovascular risk factors, and CVD have been reported in several population-based studies from North America and Asia.1 However, recent publications from Europe found no association or only an association between severe AD and CVD.2-4 The association between adult AD and CVD would be consistent with a recent study that showed the occurrence of severe CVD and metabolic abnormalities in a mouse model of severe dermatitis resulting from persistent release of IL-1 family cytokines from the skin.5 Interestingly, both skin and systemic pathologies were ameliorated by treatment with anti–IL-1α and anti–IL-1β neutralizing antibodies. [...]we have shown that biomarker expression profiles in moderate-to-severe AD patients are clearly different from those in healthy controls, which confirms the presence of systemic inflammation in AD patients and supports the hypothesis that AD is a systemic disorder.